Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.

Evanthia Galanis; S. Keith Anderson; C. Ryan Miller; Jann N. Sarkaria; Kurt Jaeckle; Jan C. Buckner; Keith L. Ligon; Karla V. Ballman; Dennis F. Moore; Michael Nebozhyn; Andrey Loboda; David Schiff; Manmeet Singh Ahluwalia; Eudocia Q. Lee; Elizabeth R. Gerstner; Glenn J. Lesser; Michael Prados; Stuart A. Grossman; Jane Cerhan; Caterina Giannini; Patrick Y. Wen

doi:10.1093/NEUONC/NOX161

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.

Evanthia Galanis, S. Keith Anderson, C. Ryan Miller, Jann N. Sarkaria, Kurt Jaeckle, Jan C. Buckner, Keith L. Ligon, Karla V. Ballman, Dennis F. Moore, Michael Nebozhyn, Andrey Loboda, David Schiff, Manmeet Singh Ahluwalia, Eudocia Q. Lee, Elizabeth R. Gerstner, Glenn J. Lesser, Michael Prados, Stuart A. Grossman, Jane Cerhan, Caterina GianniniPatrick Y. Wen

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Neuro-oncology
Volume	20
DOIs	https://doi.org/10.1093/NEUONC/NOX161
State	Published - Mar 27 2018

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1093/NEUONC/NOX161License: Unspecified

Cite this

Galanis, E., Anderson, S. K., Miller, C. R., Sarkaria, J. N., Jaeckle, K., Buckner, J. C., Ligon, K. L., Ballman, K. V., Moore, D. F., Nebozhyn, M., Loboda, A., Schiff, D., Ahluwalia, M. S., Lee, E. Q., Gerstner, E. R., Lesser, G. J., Prados, M., Grossman, S. A., Cerhan, J., ... Wen, P. Y. (2018). Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Neuro-oncology, 20. https://doi.org/10.1093/NEUONC/NOX161

Galanis, E, Anderson, SK, Miller, CR, Sarkaria, JN, Jaeckle, K, Buckner, JC, Ligon, KL, Ballman, KV, Moore, DF, Nebozhyn, M, Loboda, A, Schiff, D, Ahluwalia, MS, Lee, EQ, Gerstner, ER, Lesser, GJ, Prados, M, Grossman, SA, Cerhan, J, Giannini, C & Wen, PY 2018, 'Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.', Neuro-oncology, vol. 20. https://doi.org/10.1093/NEUONC/NOX161

@article{38a0838605ed4a08b13fdbd7b9726955,

title = "Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.",

author = "Evanthia Galanis and Anderson, \{S. Keith\} and Miller, \{C. Ryan\} and Sarkaria, \{Jann N.\} and Kurt Jaeckle and Buckner, \{Jan C.\} and Ligon, \{Keith L.\} and Ballman, \{Karla V.\} and Moore, \{Dennis F.\} and Michael Nebozhyn and Andrey Loboda and David Schiff and Ahluwalia, \{Manmeet Singh\} and Lee, \{Eudocia Q.\} and Gerstner, \{Elizabeth R.\} and Lesser, \{Glenn J.\} and Michael Prados and Grossman, \{Stuart A.\} and Jane Cerhan and Caterina Giannini and Wen, \{Patrick Y.\}",

note = "Vorinostat, a histone deacetylase (HDAC) inhibitor, has shown radiosensitizing properties in preclinical studies. This open-label, single-arm trial evaluated the maximum tolerated dose (MTD; phase I) and efficacy (phase II) of vorinostat combined with standard chemoradiation in newly diagnosed glioblastoma. Patients received oral vorinostat (300 or 400 mg/day) on days 1-5 weekly during temozolomide chemoradiation.",

year = "2018",

month = mar,

day = "27",

doi = "10.1093/NEUONC/NOX161",

language = "American English",

volume = "20",

journal = "Neuro-oncology",

}

TY - JOUR

T1 - Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.

AU - Galanis, Evanthia

AU - Anderson, S. Keith

AU - Miller, C. Ryan

AU - Sarkaria, Jann N.

AU - Jaeckle, Kurt

AU - Buckner, Jan C.

AU - Ligon, Keith L.

AU - Ballman, Karla V.

AU - Moore, Dennis F.

AU - Nebozhyn, Michael

AU - Loboda, Andrey

AU - Schiff, David

AU - Ahluwalia, Manmeet Singh

AU - Lee, Eudocia Q.

AU - Gerstner, Elizabeth R.

AU - Lesser, Glenn J.

AU - Prados, Michael

AU - Grossman, Stuart A.

AU - Cerhan, Jane

AU - Giannini, Caterina

AU - Wen, Patrick Y.

N1 - Vorinostat, a histone deacetylase (HDAC) inhibitor, has shown radiosensitizing properties in preclinical studies. This open-label, single-arm trial evaluated the maximum tolerated dose (MTD; phase I) and efficacy (phase II) of vorinostat combined with standard chemoradiation in newly diagnosed glioblastoma. Patients received oral vorinostat (300 or 400 mg/day) on days 1-5 weekly during temozolomide chemoradiation.

PY - 2018/3/27

Y1 - 2018/3/27

UR - http://europepmc.org/abstract/MED/29016887

U2 - 10.1093/NEUONC/NOX161

DO - 10.1093/NEUONC/NOX161

M3 - Article

VL - 20

JO - Neuro-oncology

JF - Neuro-oncology

ER -

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.

Disciplines

Access to Document

Other files and links

Cite this